Patent ID: 7781437

Claim:
A compound having the structure shown in Formula 1: or a pharmaceutically acceptable salt thereof, wherein: G is selected from the group consisting of H 2 N(C═O)—and a 5-membered heteroaryl or heterocyclenyl ring, said 5-membered heteroaryl or heterocyclenyl ring is selected from the group consisiting of dihydroimidazole, imidazole, dihydrooxazole, oxazole, dihydrooxadiazole, oxadiazole, triazole, and tetrazole, and wherein said heteroaryl or heterocyclenyl ring can be either (i) unsubstituted, or (ii) optionally independently substituted on one or more ring carbon atoms with one or more R 9 substituents, L is O; Z is N; R 3 is H, alkyl, —CN, haloalkyl or halogen; R 6 is selected from the group consisting of H, alkyl, arylalkyl, and alkylaryl; the R 9 moieties can be the same or different, each being independently selected from the group consisting of H, —CF 3 , —CH 2 CH 2 OH, —CH 2 CH 2 NH 2 , —NH 2 , —NHCH 3 , —N(H)CH 2 CH 3 , —N(H)CH(CH 3 ) 2 , —N(H)CH 2 CH 2 CH 3 , —N(H)CH 2 C(═O)OCH 3 , and —N(H)CH 2 CH 2 OH; the R 10 moieties can be the same or different, each being independently selected from the group consisting of H and alkyl; the R 11 moieties can be the same or different, each being independently selected from the group consisting of H and alkyl; R 12 is H or alkyl; ring D is a six membered aryl or heteroaryl ring having 0-4 N heteroatoms, wherein ring D is unsubstituted or optionally substituted with 1-5 independently selected R 20 moieties; the R 20 moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, halogen, and amino, Y is selected from the group consisting of —CH 2 —and —C(═O)—; m is 0 to 2; n is 0 to 2.